¶ MLKL Protein (Mixed Lineage Kinase Domain-Like)
Mlkl Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
MLKL (Mixed Lineage Kinase Domain-Like) is the terminal effector of necroptosis, a programmed form of cell death. It executes membrane permeabilization and cell lysis downstream of the RIPK3 activation.
| Property | Value |
|----------|-------|
| Gene Symbol | MLKL |
| Protein Name | Mixed Lineage Kinase Domain-Like |
| UniProt ID | Q8TBX5 |
| Molecular Weight | ~54 kDa |
| Protein Family | RHIM domain-containing |
| Expression | Ubiquitous |
MLKL is the executor of necroptosis:
- Binds to phosphorylated RIPK3
- Undergoes conformational change
- Forms oligomers
- Translocates to plasma membrane
- Creates ion channels
- Leads to cell swelling and lysis
- MLKL-mediated necroptosis in neurons
- Elevated in AD brain tissue
- Contributes to neuronal loss
- Links to neuroinflammation
- MLKL activation in dopaminergic neurons
- Necroptosis in PD models
- Therapeutic target
- MLKL in motor neuron death
- Disease progression mechanisms
- MLKL mediates ischemic injury
- Necroptosis in stroke
- MLKL inhibitors
- Necroptosis blockers
- Anti-inflammatory strategies
The study of Mlkl Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- MLKL Gene - Gene encoding this protein
- RIPK3 Protein - Upstream kinase activating MLKL
- Necroptosis Pathway - Programmed necrotic cell death
- Neuroinflammation Pathway - Inflammatory signaling
- Alzheimer's Disease MLKL in AD
- Membrane rupture
- DA- Inflammation amplification
- MLKL conformational changes
- Tissue-specific necroptosis
- Biomarkers for necroptosis
- Combination therapy approaches
- Phospho-MLKL detection
- Necroptosis-associated DAMPs
- Circulating MLKL fragments
- ATP-analog MLKL inhibitors
- Allosteric modulators
- Antibody-based approaches
- IL-1 release
- IL-6 production
- TNF-α amplification
- Chemokine secretion
- Organelle swelling
- Nuclear condensation
- Cellular disintegration